Halozyme Therapeutics, Inc. (LON:0J2O)
52.87
-0.22 (-0.41%)
At close: Jun 20, 2025
Halozyme Therapeutics Revenue
Halozyme Therapeutics had revenue of $264.86M USD in the quarter ending March 31, 2025, with 35.22% growth. This brings the company's revenue in the last twelve months to $1.08B, up 25.65% year-over-year. In the year 2024, Halozyme Therapeutics had annual revenue of $1.02B with 22.44% growth.
Revenue (ttm)
$1.08B
Revenue Growth
+25.65%
P/S Ratio
5.76
Revenue / Employee
$3.10M
Employees
350
Market Cap
4.83B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.02B | 186.07M | 22.44% |
Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 42.56B |
GSK plc | 31.53B |
Haleon | 11.23B |
Smith & Nephew | 4.64B |
ConvaTec Group | 1.83B |
Hikma Pharmaceuticals | 2.50B |
HUTCHMED (China) | 503.39M |
Indivior | 905.57M |
Halozyme Therapeutics News
- 5 days ago - Halozyme Therapeutics: The Waters Become Muddled - Seeking Alpha
- 8 days ago - Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today - Benzinga
- 16 days ago - Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga
- 23 days ago - Halozyme to Participate at Upcoming Investor Conferences - PRNewsWire
- 23 days ago - What's Driving the Market Sentiment Around Halozyme Therapeutics? - Benzinga
- 23 days ago - Price Over Earnings Overview: Halozyme Therapeutics - Benzinga
- 23 days ago - Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - PRNewsWire
- 27 days ago - Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Benzinga